Odogwu, L., Mathieu, L., Goldberg, K. B., Blumenthal, G. M., Larkins, E., Fiero, M. H., . . . Pazdur, R. (2017). FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation. Oncologist.
Styl cytowania ChicagoOdogwu, Lauretta, et al. "FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation." Oncologist 2017.
Styl cytowania MLAOdogwu, Lauretta, et al. "FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation." Oncologist 2017.
Uwaga: Te cytaty mogą odróżniać się od wytycznej twojego fakultetu..